Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 3/20 | 0.41 |
| ▸ | CTSL | P07711 | 3/20 | 0.41 |
| ▸ | CTSS | P25774 | 3/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13303252 | 0.97 | ATM (0.48) | ATMMAPTSYKCTSKCTSL | |
| SCHEMBL25907516 | 0.93 | ATM (0.50) | ATMMAPTSYKCTSKCTSL | |
| SCHEMBL30550771 | 0.93 | ATM (0.50) | ATMMAPTSYKCTSKCTSL | |
| SCHEMBL13303250 | 0.82 | ATM (0.48) | ATMSYKCTSKCTSLCTSS | |
| SCHEMBL18157219 | 0.80 | ATM (0.53) | ATMSYKCTSKCTSLCTSS | |
| SCHEMBL12262714 | 0.80 | ATM (0.50) | ATMSYKCTSKCTSLCTSS | |
| SCHEMBL25321397 | 0.78 | P2RX7 (0.46) | ATMCTSK | |
| SCHEMBL25321389 | 0.78 | P2RX7 (0.46) | ATMCTSK | |
| SCHEMBL25907518 | 0.78 | P2RX7 (0.46) | ATMCTSK | |
| SCHEMBL26782894 | 0.78 | P2RX7 (0.46) | ATMCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365529-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. | 2023-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365529-A1 | PARP7 INHIBITORS | PARP1, PARP11, PARP2 | ATM 206/4885MAPT 2243/4885SYK 2284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.